Drug Profile
LEO 22811
Alternative Names: LEO-22811Latest Information Update: 29 Aug 2015
Price :
$50
*
At a glance
- Originator LEO Pharma
- Class Anti-inflammatories
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Psoriasis
Most Recent Events
- 29 Aug 2015 No recent reports on development identified - Phase-I for Psoriasis (In volunteers) in United Kingdom (PO)
- 29 Aug 2015 No recent reports on development identified - Phase-II for Psoriasis in France and Canada (PO)
- 22 Nov 2010 Phase-II clinical trials in Psoriasis in Canada (PO)